You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 439 Dual modes of action for anti-TIM-3 antibody MBG453 in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML): preclinical evidence for immune-mediated and anti-leukemic activity

Citation Tools

Article menu

Download PDFPDF

Regular and young investigator award abstracts
Combination immunotherapies
439 Dual modes of action for anti-TIM-3 antibody MBG453 in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML): preclinical evidence for immune-mediated and anti-leukemic activity

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Sabatos-Peyton C, Longmire T, Baker L, et al
439 Dual modes of action for anti-TIM-3 antibody MBG453 in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML): preclinical evidence for immune-mediated and anti-leukemic activity
Journal for ImmunoTherapy of Cancer 2020;8:doi: 10.1136/jitc-2020-SITC2020.0439